[Retracted] Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis

Table 1

Characteristics of the included literature.

Author, year	Sample size	Diagnostic criteria	Male%	Age (years)		Course of the disease		Treatment intervention	Control intervention	Period of treatment (months)	Outcome indicator
				Experimental group	Control group	Experimental group	Control group
Hu et al., [14]	116	Clinical symptoms, colonoscopy, pathology	51.7%	42.37 ± 2.87	42.61 ± 2.82	8.71 ± 2.42	8.94 ± 2.4	HQT^1+mesalazine^a	Mesalazine^a	2	Cure rate, total effective rate, clinical symptom score
Ding et al., [15]	126	Clinical symptoms, colonoscopy, pathology	53.2%	43.5 ± 9.6	42.4 ± 8.7	9.5 ± 3.2	9.2 ± 3.5	HQT^2+mesalazine^a	Mesalazine^a	2	Cure rate, total effective rate, TCM syndrome score, IL-6/10/TNF-α IgG/IgM/IgA
Yan [16]	82	Clinical symptoms, imaging	54.9%	36.68 ± 6.52	36.74 ± 6.58	6.52 ± 3.23	6.47 ± 3.18	HQT^1+mesalazine^a	Mesalazine^a	2	Cure rate, total effective rate
Wang and Wang [17]	78	Clinical symptoms, colonoscopy	57.7%	35.36 ± 4.32	35.18 ± 4.29	3.91 ± 0.45	3.86 ± 0.41	HQT^1+mesalazine	Mesalazine	3	Cure rate, total effective rate, adverse reactions
Lu [18]	95	Clinical symptoms, colonoscopy, pathology	51.6%	36.57 ± 6.59	35.97 ± 6.29	NA	NA	HQT^1+mesalazine^b	Mesalazine^b	2	IL-10/TNF-α,IgG/IgM/IgA
Yang [19]	68	Clinical symptoms, colonoscopy, pathology, imaging	48.5	42.6 ± 12.7	41.5 ± 12.5	NA	NA	HQT^2+mesalazine^b	Mesalazine^b	2	Cure rate, total effective rate, IL-6/10/TNF-α

“1” represents decoction of HQT, “2” represents granule of HQT; “a” represents mesalazine granules or sustained-release granules, and “b” represents mesalazine enteric-coated tablets.